NFKB1 and diabetic kidney disease: Preclinical studies in a rat model of DKD confirm that TP mitigates renal injury precisely by targeting this axis: it rebalances the Th1/Th2 ratio, suppresses NF-κB activation, and consequently, inhibits the infiltration of pathogenic monocytes/macrophages (Guo et al., 2016).